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Background: Themajority of the disease-causingmutations affect protein stability, but not functional sites and are
amenable, in principle, to be treatedwith pharmacological chaperones. These drugs enhance the thermodynamic
stability of their targets. Fabry disease, a disorder caused bymutations in the gene encoding lysosomal alpha-ga-
lactosidase, represents an excellentmodel system to develop experimental protocols to test the efﬁciency of such
drugs.
Methods: The stability of lysosomal alpha-galactosidase under different conditions was studied by urea-induced
unfolding followed by limited proteolysis and Western blotting.
Results:Wemeasured the concentration of urea needed to obtainhalf-maximal unfolding because this parameter
represents an objective indicator of protein stability.
Conclusions: Urea-induced unfolding is a versatile technique that can be adapted to cell extracts containing tiny
amounts of wild-type ormutant proteins. It allows testing of protein stability as a function of pH, in the presence
or in the absence of drugs. Results are not inﬂuenced by the method used to express the protein in transfected
cells.
General signiﬁcance: Scarce and dispersed populations pose a problem for the clinical trial of drugs for rare dis-
eases. This is particularly true for pharmacological chaperones that must be tested on each mutation associated
with a given disease. Diverse in vitro tests are needed.We used amethod based on chemically induced unfolding
as a tool to assess whether a particular Fabry mutation is responsive to pharmacological chaperones, but, by no
means is our protocol limited to this disease.© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY license.1. Introduction
The reduction in protein stability is the most common cause of
monogenic diseases [1]. This knowledge paves the way to a new
therapeutic approach. Pharmacological chaperones (PC) are small mol-
ecules that stabilize the mutant proteins, increase their intracellular
concentration and consequently their intracellular activity. Because of
their effect on the apparent stability of proteins they can also be de-
scribed as “thermodynamic drugs”. The therapeutic approach with PC
is currently being tested not only for lysosomal storage diseases [2]abry disease; AGAL, lysosomal
, circular dichroism
iologia, Università Federico II,
ndreotti), v_citro@libero.it
llis@unina.it (M.V. Cubellis).
. Open access under CC BY license.like Fabry [3,4], Gaucher [5,6] or Pompe [7,8], but also for other diseases
like Phenylketonuria [9].
In order to develop new methodologies to test PC, we used Fabry
disease (FD) as a model system.
Fabry is an X-linked disease which affects not only male individuals,
but also heterozygote female carriers, although in a milder form. It is
due to mutations in the gene encoding lysosomal alpha-galactosidase
(AGAL) [HGNC: GLA; UNIPROT: AGAL_HUMAN], a dimeric protein,
synthesized and glycosylated in the endoplasmic reticulum and
transported into lysosomes. The clinical picture of FD is rather complex
because more than 400 missense mutations have been described and a
good share of them is private. There is already an approved therapy for
FD which consists in the infusion of the recombinant human protein
(for a review on FD [10]). Unfortunately this therapy is very expensive
and in many cases it causes the formation of antibodies against the
exogenous protein [11]. For some mutations PC offer an alternative
therapeutic approach. Chemicals to be used as PC can be found
exploiting their ability to stabilize the wild type enzyme. Once they
are found, they must be tested on each mutation because only a
percentage of the cases will be responsive. This holds for FD and is in
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Fig. 1. Urea-induced melting proﬁle of wild-type lysosomal alpha-galactosidase
(Fabrazyme®) recorded by circular dichroism. The protein (0.3 mg/ml inMcIlvaine buffer
at pH 7.4) was equilibrated with urea (from 0 to 6 M) in the presence of 1-deoxy-
galactonojirimycin (DGJ) 40 μM or not, then ellipticity at 223 nm was recorded. Data
were expressed as mean residue ellipticity.
1215G. Andreotti et al. / Biochimica et Biophysica Acta 1840 (2014) 1214–1224general true also for other diseases. An imino-sugar that resembles ga-
lactose, 1-deoxy-galactonojirimycin, also known as AT1001 or DGJ, is
in clinical trial phase 3 for FD [12]. Some methods have been proposed
[13–16] to predict the cases which should be responsive to this drug,
but tests in vitro are preferable. Classical methods to evaluate thermo-
dynamic stability, which are very useful to ﬁnd chemicals effective on
wild type enzymes, are not feasible for the screening of mutants, be-
cause they require milligrams of puriﬁed proteins. Currently the effec-
tiveness of PC is evaluated on patient's cells cultured in a medium
supplemented or not with the drug [17–21]. Mutants are quantiﬁed
by western blot or assayed enzymatically in the cell extracts without
prior puriﬁcation. Alternatively the half life of the mutants can be mea-
sured by pulse chase, but in these cases radioactive labeling is required
[22]. Unfortunately patient derived xenografts or cells might not be
available and in any case are not useful for female patients who are a
mosaic of cells expressing either wild type ormutant AGAL. Transfectedurea, M
A -DGJ
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Fig. 2.Urea-inducedmelting proﬁle ofwild-type lysosomal alpha-galactosidase (Fabrazyme®) r
buffer at pH 7.4) was equilibrated with urea (from 0 to 6 M) in the presence of 1-deoxy-galac
proteolysis with thermolysin (1 min at 37 °C, 1:5 protease to substrate ratio) and then analyze
+ DGJ, panel B). The intensity of the bands was quantiﬁed and expressed as relative intensitycells, which offer a useful surrogate to patient cells [18,21–27], also
present some disadvantages. In fact, under the high expression condi-
tions that are usually employed, biosynthetic machinery might be satu-
rated preventing the correct assessment of drug induced mutant
stabilization.Moreover, results are reliable only if the efﬁciency of trans-
fections in positive and negative controls, i.e. cells treated or not treated
with PC, is exactly the same.
A good solution to test PC would be to adapt a classic method to
measure thermodynamic stability of mutants produced in the cells in
a small quantity and unpuriﬁed, in the presence or in the absence of
the drug. In this article we propose to borrow a thermodynamic assay
which is usually employed to assess protein stability for another
purpose, that is testing drug responsiveness, and we suggest to use
unfolding induced by urea [25]. Wild type AGAL was challenged with
urea and results obtainedmonitoring unfoldingwith circular dichroism,
pulse proteolysis or pulse proteolysis followed by western blot
were compared. The last method which is designed for experiments
on cell extracts containing low amounts of the protein of interest, was
tested on four AGAL mutants. One of these, L300F-AGAL (c.898CNT,
p.L300F) was produced using different transfection protocols in order
to assess the reproducibility of results. Different pH buffers were used
to mimic the conditions encountered by the protein in different cellular
compartments.
2. Results
2.1. Chemically induced alpha-galactosidase unfolding
AGAL (Fabrazyme®)(6 μM per monomer concentration) was incu-
bated at 20 °C inMcIlvaine buffer pH 7.4 in the presence of various con-
centrations of urea until unfolding equilibrium was obtained and a
16–18 h incubation was considered adequate to reach equilibrium in
the subsequent experiments. We ﬁnd a strong stabilizing effect of DGJ
against urea denaturation, a sharp transition in the case of apo-
enzyme and a broad transition in the case of the complexed enzyme
(Fig. 1) Although thermally or chemically induced unfolding describes
different processes, the reduced steepness of the denaturation curve
in the presence of the drug conﬁrms the results obtained by Petsko
and coworkers [28] who found a coincidence of calorimetric and van't
Hoff enthalpies for the free enzyme, but not for the complexed enzyme.C
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ecorded by pulse-proteolysis and SDS-PAGE analysis. The protein (0.3 mg/ml inMcIlvaine
tonojirimycin (DGJ) 40 μM or not, then an aliquot of each sample was subjected to pulse
d by SDS-PAGE. The protein was visualized by Coomassie Blue Staining (− DGJ, panel A;
(panel C).
urea, M urea, M urea, M
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Fig. 3. Urea-induced unfolding proﬁles of wild-type lysosomal alpha-galactosidase present in raw cell extracts recorded by pulse-proteolysis and western-blot. Lysates of COS7 cells expressing wild-type lysosomal alpha-galactosidase were mixed
with the denaturant to obtain ﬁnal urea concentrations ranging from 0 to 6 M. The experiment was conducted in McIlvaine buffer at pH 4.5 (panel A), 5.2 (panel B) or 7.4 (panel C) either in the absence or in the presence of 1-deoxy-
galactonojirimycin (DGJ) 40 μM. Pulse proteolysis (1 min at 37 °C, 1:5 protease to substrate ratio) was performed after the equilibrium was reached to digest unfolded protein and then analyzed by western-blot. Thermolysin was used when op-
erating at pH 5.2 or 7.4, pepsin when operating at pH 4.5. The intensity of the bands was quantiﬁed and data were expressed as fraction of the zero urea sample.
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Fig. 4. Comparison between glycosylation states of wild-type lysosomal alpha-
galactosidase produced in COS7 cells and Fabrazyme®. Fabrazyme® and lysates of COS7
cells expressing wild-type lysosomal alpha-galactosidase were incubated overnight at
37 °C in the presence of N-Glycosidase F. The samples were pre-treated with SDS 0.1%
and EDTA 20 mM, boiled and cooled and NP-40 was added to 0.7%. Samples were com-
pared by SDS-PAGE and western blot: Fabrazyme® not treated (lane 1) or treated with
N-Glycosidase F (lane 2); wild-type lysosomal alpha-galactosidase expressed in COS7
non-treated (lane 3) or treated with N-Glycosidase F (lane 4).
1217G. Andreotti et al. / Biochimica et Biophysica Acta 1840 (2014) 1214–1224A two statemodel can account for the unfolding of the apo-enzyme, but
not for that of the complex. For this reason our analysis is limited to the
midpoint urea concentration C0.5 of the normalized data as an operative
measure of protein stability. This value can be determined quite accu-
rately and is little affected by the mechanism of the unfolding. We are
aware of the fact that a precise measure of the free energy of unfolding
in water, which is outside the scope of this paper, would require the
evaluation of the dependence of the free energy on denaturant concen-
tration, i.e. the assessment of m-values [29]. However this value cannoturea, M
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Fig. 5. Urea-induced unfolding proﬁles of L300F lysosomal alpha-galactosidase present in raw
L300F lysosomal alpha-galactosidase were mixed with the denaturant to obtain ﬁnal urea con
5.2 (panel A) or 7.4 (panel B) either in the absence or in the presence of DGJ 40 μM. Pulse prot
libriumwas reached to digest unfolded protein and then analyzed by western-blot. The intensitbe determined very accurately and its correlationwith stability has been
well documented mostly for monomeric proteins that unfold with a
two-state mechanism and without ligands.
In the absence of DGJ C0.5 is at 2.0 ± 0.2 M urea (Fig. 1) whereas,
due to the strong stabilizing effect of the drug and consequently to the
difﬁculty of determining a true endpoint of the melting curve, in the
presence of DGJ only an approximate C0.5 can be estimated above 4 M
urea.
The same samples, which had been analyzed by circular dichroism
(CD), were incubated with thermolysin (1:5 protease to Fabrazyme®
ratio by weight). After having inactivated the protease by addition of
EDTA, the samples were analyzed by SDS-PAGE (Fig. 2 panels A and
B). The intensity of the bands was quantiﬁed and the proﬁles obtained
(Fig. 2 panel C) conﬁrm the stabilizing effect of DGJ. In particular we
observe that the transition in the absence of DGJ is sharp whereas a
more complex unfolding process occurs in the presence of DGJ. Hence
the effect observed with a “classic”method, i.e. urea-induced denatur-
ation monitored by circular dichroism (Fig. 1), is reproduced with
pulse-proteolysis [30].2.2. Scaling down chemically induced alpha-galactosidase unfolding for the
analysis of mutants
AGAL was produced in COS7 cells transiently transfected with an
expression vector. Whole cell extracts were aliquoted and incubated
with variable concentration of urea, in the presence or in the absence7.4
-
+
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extracts recorded by pulse-proteolysis and western-blot. Lysates of COS7 cells expressing
centrations ranging from 0 to 6 M. The experiment was conducted in McIlvaine buffer at
eolysis (1 min at 37 °C, 1:5 thermolysin to substrate ratio) was performed after the equi-
y of the bandswas quantiﬁed and data were expressed as fraction of the zero urea sample.
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Fig. 6.Urea-induced unfolding proﬁles of D244H, Q280K and R301P lysosomal alpha-galactosidasemutants present in raw cell extracts recorded by pulse-proteolysis andwestern-blot. Lysates of COS7 cells expressingD244H (panel A), Q280K (panel
B) or R301P (panel C) lysosomal alpha-galactosidase weremixedwith the denaturant to obtain ﬁnal urea concentrations ranging from 0 to 5 M. The experiment was conducted inMcIlvaine buffer at pH 7.4 either in the absence or in the presence of
DGJ 40 μM. Pulse proteolysis (1 min at 37 °C, 1:5 thermolysin to substrate ratio)was performed after the equilibriumwas reached to digest unfolded protein and then analyzed bywestern-blot. The intensity of the bandswas quantiﬁed and datawere
expressed as fraction of the zero urea sample.
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1219G. Andreotti et al. / Biochimica et Biophysica Acta 1840 (2014) 1214–1224of 40 μM DGJ. After 16–18 h of equilibration, the unfolded proteins
were digested proteolytically and the residual AGAL was quantiﬁed by
western blot. Three sets of experiments were conducted at different
pHs and are summarized in Fig. 3.
Thermolysin was added (1:5 ratio with total protein in the ex-
tracts by weight) when the denaturation had been carried out at
pH 7.4 or 5.2. Pepsin was added (1:5 ratio with total protein in the
extracts by weight) when the denaturation had been carried out at
pH 4.5.
Fig. 3 panel C shows that at neutral pH DGJ stabilizes the protein
shifting the midpoint concentration from 1.8 ± 0.1 M to 3.5 ± 0.2 M
urea. C0.5 is slightly lower for the human enzyme expressed in
COS7 cells than for Fabrazyme®. This can be explained by a differ-
ent glycosylation of the enzyme. In Fig. 4 we compare AGAL pro-
duced in COS7 cells to Fabrazyme®. Their electrophoretic
mobilities are different, but become the same upon treatment with
N-Glycosidase F.
The enzyme is more stable at pH 5.2 (Fig. 3 panel B) compared to
pH 7.4 (Fig. 3 panel C) with a C0.5 approximately at 4 M urea in the ab-
sence of the DGJ and it is resistant to denaturation even at 6 M urea in
the presence of the drug. On the other hand, we observe a reduction
in the stability at pH 4.5 and C0.5 values drop to 0.1 M in the absence
of DGJ or to 1.2 M urea in the presence of DGJ.
L300F-AGAL [31] is a mutant with less than 10% of the wild type ac-
tivity. COS7 cells expressing this mutant recover activity when they are
exposed to DGJ [27].We tested thermodynamic stability of L300F-AGAL
by challenging it with urea. A single transfection in COS7 cells was re-
quired to produce the extract, 50 μg proteins in total, that was aliquoted
and treated with different concentrations of urea in the presence or in
the absence of DGJ. Fig. 5 shows the results obtained at pH 5.2 (panel
A) or 7.4 (panel B).
This experiment demonstrates that the mutant is less stable than
wild type both at neutral and at acidic pH, yet it becomes as stable as
the wild type when treated with DGJ. Moreover, we observe that
L300F-AGAL is more stable at pH 5.2 than at pH 7.4.
Besides L300F-AGAL, other mutations associatedwith classic clinical
manifestations, Q280K-AGAL (c.838CNA, p.Q280K) [32], D244H-AGAL
(c.730GNC, p.D244H) [33], R301P-AGAL (c.902GNC, p.R301P) [34]
were tested at pH 7.4 with increasing amounts of urea, limited proteol-
ysis andwestern blot. Results are shown in Fig. 6.We chose neutral con-
ditions because they reﬂect the environment of the endoplasmic
reticulum and the same expression protocol based on Lipofectamine®R301P + 
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Fig. 7. Correlation between urea C0.5 and alpha galactosidase increase. Urea concentration
was from Figs. 5 and 6 (this paper); alpha galactosidase activity is expressed as
mut_activity + DGJ / WT_activity − DGJ × 100. The Pearson correlation coefﬁcient is
0.94.2000 which had already been exploited for a previous experiment
[27]. In that case transfected cells were cultured in a medium supple-
mented or not with the drug and AGAL activity was assayed enzymati-
cally. C0.5 values derived by the plots in Fig. 5 panel B or Fig. 6 correlate
with the AGAL activitymeasured in cell extracts [27] (Fig. 7 Pearson cor-
relation coefﬁcient r = 0.94).
We compared the effect of different transfection protocols on the
results obtained either assaying the enzymatic activity in cells ex-
posed or not exposed to DGJ or with the novel method based on
chemically induced unfolding. The experiments were carried out
on L300F-AGAL. Recipient hosts were COS7 cells or HEK293, either
adherent cells or in suspension, and transfection reagents were
Lipofectamine® ltx, Fugene ®HD or calcium phosphate. To test the
currently employed method, after transfection, the cells were
supplemented or not with 0.02 mM DGJ and AGAL activity assayed
in cell free extracts. The value obtained was either divided by the
protein concentration (Fig. 8 panel A) or normalized to luciferase
activity (Fig. 8 panel B). Responsiveness can be deﬁned as AGAL ac-
tivity of a givenmutant after administration of DGJ to the cells, divid-
ed by the activity of wild type AGAL expressed in the same cells non-
exposed to the drug, multiplied by 100, i.e. resp = (mut_activity +
DGJ / WT_activity − DGJ × 100). Different values are obtained if
the activity is normalized considering protein concentration
(resp_a) or transfection efﬁciency (resp_b). In terms of responsive-
ness, the results shown in Fig. 8 are consistent although outliers
are observed. We tested L300F-AGAL produced in HEK293 using
lipofectamine (resp_a = 32%; resp_b = 55%), or calcium phosphate
(resp_a = 68%; resp_b = 81%), or in COS7 using calcium phosphate
(resp_a = 290%; resp_b = 51%) andWT-AGAL produced in HEK293
using lipofectamine or calcium phosphate with the novel method
based on chemically induced unfolding. In this case the transfec-
tion was carried out on adherent cells without addition of DGJ be-
fore the lysis. Results in Fig. 9 show that the concentration of urea
needed for half denaturation is little inﬂuenced by the transfection
protocol.3. Discussion
Pharmacological chaperones work because they stabilize mutant
proteins and themethod based on thermodynamic analysis is designed
to assess this property straightforwardly.
Thermodynamic analysis allows the association of a quantiﬁ-
able parameter to the stability of proteins in a given state. Melting
temperatures, free energies or enthalpies of unfolding, midpoint
denaturant concentration, and m-values help us evaluate the sta-
bility of wild type and mutant forms of a protein under different
environmental conditions, pH or ligands. In particular the thermal
shift assay proved to be a useful method to test pharmacological
chaperones on puriﬁed proteins [35]. This method, however, can-
not be exploited to analyze mutants, unless they are expressed in
large amounts and puriﬁed. Such a pre-requisite is unfeasible in
the majority of cases. On the other hand, urea induced denatur-
ation can be monitored by limited proteolysis followed by electro-
phoresis separation exploiting the fact that unfolded proteins are
more sensitive to proteases than their folded counterparts. The
method can be adapted to raw extracts. We demonstrated that re-
sults obtained by limited proteolysis are consistent with those ob-
tained by more conventional optical techniques in the case of
Fabrazyme®.
Urea-induced unfolding allows the assignment of a useful mea-
sure of stability to a protein in a given state that is the half-
denaturation urea concentration, C0.5. We demonstrated that urea-
induced unfolding can be exploited to test the stability of wild type
or mutant AGAL in cell extracts and the capacity of chaperones to sta-
bilize the enzyme.
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Fig. 8.Alpha-galactosidase activity resulting from 1-deoxy-galactonojirimycin administration in transfected cells. Comparison between different cell hosts and transfectionmethods. COS7
or HEK293 cells were co-transfected with pCMV6-AC harboring L300F-AGAL gene and with pMIR vector harboring the luciferase reporter gene. Transfections were performed with
Lipofectamine® ltx, Fugene® HD or CalPhos™Mammalian Transfection Kit, either using cell in adhesion (A) or in suspension (S). Cells were than cultivated with (+) or without (−)
0.02 mM DGJ. After cell lysis AGAL activity and luciferase activity were measured. Four independent experiments were performed in the presence of DGJ, two without DGJ. Alpha galac-
tosidase activity (expressed as mut_activity / WT_activity − DGJ × 100) was normalized by protein concentration in panel A and by luciferase activity in panel B.
1220 G. Andreotti et al. / Biochimica et Biophysica Acta 1840 (2014) 1214–1224Usually the efﬁcacy of PC is evaluated on the patient's cells or in cells
transfected with an expression vector carrying the mutation and cul-
tured in a medium supplemented or not with the drug. We compared
the data obtained in different labs with this method. We found 15
responsive mutations which have been tested in different labs
[19,20,22,24].Fig. 9. Stability enhancement of lysosomal alpha galactosidase by 1-deoxy-galactonojirimycin
HEK293 cells transfected with different methods and expressing L300F (panels A, B, and C) or w
to obtain ﬁnal urea concentrations ranging from 0 to 6 M. The experiment was conducted in M
teolysis (1 min at 37 °C, 1:5 thermolysin to substrate ratio)was performed after the equilibrium
the bands was quantiﬁed and data were expressed as fraction of the zero urea sample.We obtained the responsiveness in percentage deﬁned as the
AGAL activity of a given mutant after administration of DGJ to the
cells, divided by the activity of wild type AGAL expressed in the
same cells non-exposed to the drug, multiplied by 100, i.e. resp =
(mut_activity + DGJ / WT_activity − DGJ × 100). We calculated
an average responsiveness in percentage (resp), a standard. Comparison between different cell hosts and transfection methods. Lysates of COS7 or
ild type (panels D and E) lysosomal alpha-galactosidase were mixed with the denaturant
cIlvaine buffer at pH 7.4 either in the absence or in the presence of DGJ 40 μM. Pulse pro-
was reached to digest unfoldedprotein and then analyzedbywestern-blot. The intensity of
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are in qualitative accordance, but quantitatively the extent of
responsiveness varies, with an average standard deviation,
∑ i = 115 (SDrespi), as large as 15 ± 10.
The approach based on chemically induced unfolding gives results
that are little inﬂuenced by the method chosen to express the protein.
The results are consistentwith those obtainedmeasuring the enzymatic
activity in cells exposed or not exposed to the drug [27] (Fig. 7). The
method based on chemically induced unfolding offers some advantages.
For example it consents to test proteins at different pHs. This is impor-
tant considering that, in general, chaperones are inhibitors of the enzy-
matic activity. The ideal drug for lysosomal storage disorders such as
Fabry disease, should bind the protein in the neutral compartment
where it folds and dissociates in the acidic compartment where AGAL
exerts its function. Moreover the method based on chemically induced
unfolding can be used to test lead compounds on mutants expressed
in tiny amounts and unpuriﬁed. In this case the molecules might be
yet unable to cross the cell membrane and administration in the cell
medium would be not effective.
Diverse methods to test the efﬁcacy of pharmacological chaper-
ones on individual mutations of a given disease are urgently needed.
In particular this is true for Fabry disease, a pathology characterized
by hundreds of different mutations each affecting a scarce and dis-
persed population. Clinical trials with control groups are difﬁcult as
exempliﬁed by studies carried out to test the efﬁcacy of DGJ on
male [12,26] or female [36] populations. Twenty-one out of 450 mis-
sense/nonsense mutations have been tested and only in few cases
was it possible to enroll more than one patient. Independent positive
results obtained in vitro with the thermodynamic approach and
other methods [37] might be the only support to choose the best
therapy, PC or enzyme replacement therapy for individual Fabry
patients.
4. Materials and methods
4.1. Cell cultures
The clone SC319065, which contains the full length cDNA for wild
type human AGAL inserted into the expression vector pCMV6-AC, was
purchased from Origene (Rockville, MD, USA). Q280K-AGAL, D244H-
AGAL, L300F-AGAL andR301P-AGALwere obtained by site directedmu-
tagenesis in the same vector [27]. Human embryo kidney 293 (HEK293)
and African green monkey kidney (COS7) cells were maintained in
Dulbecco's Modiﬁed Eagle's Medium (GIBCO BRL)with 10% fetal bovine
serum, 100 units/ml penicillin, and 100 mg/ml streptomycin at 37 °C in
a humidiﬁed atmosphere containing 5% CO2.
COS7 cells were transfectedwith individual plasmids using the Lipo-
fectamine®2000 (Invitrogen Molecular Probes, lifetechnologies.com)
cationic lipid reagent as previously described [27]. Transfected cells
were plated onto a 100 mm dish and cultured in DMEM containing
10% FBS in the presence of 0.02 mM DGJ at 37 °C and 5% CO2. After a
48 h incubation, the cells were washed in PBS (5 times), scraped and
harvested by centrifugation. Dry pellets were resuspended in water
and lysed by freeze-thawing.
The effect of transfection method on the quantitative assessment of
responsiveness to DGJ was tested. In assays carried out on adherent
cells, COS7 or HEK293 was seeded into 6-well plates the day before
transfection, grown to 80–90% conﬂuency, and transfected by Lipofecta-
mine® ltx (Invitrogen, lifetechnologies.com), Fugene® HD (Promega,
Italy) or CalPhos™ Mammalian Transfection Kit (Takara Bio Europe/
Clontech) according to manufacturer's with pCMV6-AC plasmids
encoding either L300F-AGAL or WT-AGAL.
In assays carried out on cells in suspension, HEK293 was harvested
by trypsin treatment, resuspended in DMEM containing 10% FBS and
supplemented with the appropriate transfection mix solution. The
cells were then distributed into wells of a six-well plate at 60%conﬂuency and allowed to adhere. The medium was substituted by
fresh DMEM, 10% FBS (3 ml).
Cellswere cultivatedwith orwithout 0.02 mMDGJ for 48 h, rinsed 5
times in PBS, scraped and harvested by centrifugation. Dry pellets were
resuspended in 50 μl of water and lysed by freeze-thawing The efﬁcien-
cy of the transfection was calculated by cotransfecting a 1:4 ratio of
pMIR vector (Applied Biosystems/Ambion, Italy) containing the lucifer-
ase gene and assaying the reporter gene activity under standard condi-
tions using ONE-Glo™ Luciferase Assay System (Promega, Italy). AGAL
activity was measured by adding 2 μl of the cell lysates to 38 μl of
AGAL assay buffer (sodium citrate 27 mM-sodium phosphate dibasic
46 mM, 4-methylumbelliferyl-alpha-D-galactopyranoside 5 mM and
N-acetyl-D-galactosamine 100 mM, pH 4.5) and incubated for 1 h at
37 °C. All chemicals were obtained from Sigma (SIGMA, Milan, Italy).
The reaction was stopped by adding 360 μl of 1 M sodium carbonate
buffer [20]. Fluorescencewas detected using a ﬂuorescence spectropho-
tometer (Cary Eclypse-Varian) at 355 nm excitation and 460 nm emis-
sion. A 4-methylumbelliferone standard curve ranging from 5 nM to
25 μM was run in parallel for conversion of ﬂuorescence data to AGAL
activity expressed as nmol/mg protein per hour.
4.2. Urea-induced unfolding
Fabrazyme® (Genzyme, Cambridge, MA) (0.3 mg/ml) was induced
to unfold by urea in McIlvaine buffer at pH 7.4, with or without
0.04 mM DGJ in a ﬁnal volume of 0.150 ml. Dilutions of the enzyme
reconstituted in water, buffer and 8 M urea were carried out in sep-
arate tubes in order to obtain the desired ﬁnal conditions where urea
concentration varied from 0 to 6 M. Molar ellipticity per mean resi-
due [ϑ]MRE@223 in deg cm2 dmol−1 was calculated from the equation
[ϑ]MRE@223 = 100∙[ϑ]obsl∙ l C where [ϑ]obs is the ellipticity measured
in degrees on a JASCO J-815 spectropolarimeter, l is the pathlength of
the cell in cm and C is the protein concentration referred to the mean
residue molecular weight. Aliquots were withdrawn from the same
samples prepared for CD measures, supplemented with CaCl2 (10 mM
ﬁnal concentration) and with the appropriate amount of thermolysin
necessary to realize a 1:5 protease to protein ratio. After 1 min incuba-
tion at 37 °C the reaction was stopped by addition of EDTA (40 mM
ﬁnal concentration). Folded undigested proteins were quantiﬁed with
a ChemiDoc XRS (Bio-Rad Laboratories, Hercules, CA-USA) systems
after having been separated by SDS-PAGE and colored by Coomassie
Blue Staining.
Urea-induced unfolding of COS7 or HEK293 cell lysates containing
wild-type AGAL or L300F-AGAL, or Q280K-AGAL, or D244H-AGAL, or
R301P-AGAL was conducted in McIlvaine buffer at pH 4.5, 5.2 or 7.4,
in a total volume of 17 μl containing 0.2 mg/ml protein, urea ranging
from 0 to 6 M, in the presence or in the absence of 0.04 mM DGJ. The
samples were incubated for 16–18 h at 20 °C.
Pulse proteolysis was performed after the equilibrium was reached
to digest unfolded proteins. The samples at pH 5.2 or 7.4 were treated
with appropriate amount of thermolysin in order to realize a 1:5 prote-
ase to substrate (total proteins) ratio. CaCl2 was also added to the reac-
tion mixture up to 10 mM. After 1 min incubation at 37 °C the reaction
was stopped by addition of EDTA (40 mM ﬁnal concentration). The
samples at pH 4.2 were treated with the appropriate amount of pepsin
in order to realize a 1:5 protease to substrate (total proteins) ratio. After
1 min incubation at 37 °C the protease was inactivated by addition of
Tris 1 M pH 9.0.
Aliquots (1 μg) were loaded onto a 12% SDS-PAGE gel and trans-
ferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA-
USA) for 2 h at 100 V in Tris-Glycine buffer containing 20% metha-
nol. The membrane was blocked with 5% (w/v) non-fat dried
skimmed milk in TBS containing Tween20 0.05% (TTBS) at 4 °C over-
night, and then treated with the primary antibody (polyclonal anti-
body produced in rabbit, Abcam 70520) diluted in TTBS 1:500 for
1 h at room temperature. After washing with an excess of TTBS, the
1223G. Andreotti et al. / Biochimica et Biophysica Acta 1840 (2014) 1214–1224membrane was treated with the secondary antibody (HRP-conjugat-
ed anti-rabbit IgG antibody produced in goat, Bio-Rad 1706515)
diluted in the TTBS solution 1:2000 for 1 h at room temperature.
After washing, the detection was performed by using the Immun-
Star WesternC chemiluminescence detection kit (Bio-Rad Laborato-
ries, Hercules, CA-USA).
4.3. Miscellaneous
N-Glycosidase F was purchased by Roche (Roche Diagnostics GmbH,
Mannheim, Germany). Deglycosylation of Fabrazyme® or AGAL
expressed in COS7 cells (9 μg, 0.3 mg/ml) was performed according to
the producer's instructions. Brieﬂy, EDTA and SDS were added to the
proteins (ﬁnal concentrations were 20 mM and 0.1% respectively).
The sampleswere boiled for 5 min, immediately cooled before the addi-
tion of NP-40 to a ﬁnal condition of 0.7% and N-Glycosidase F (1 unit)
and incubated overnight at 37 °C. Controls were run in parallel without
the addition of N-Glycosidase F. Aliquots were analyzed by SDS-PAGE
and western blotting.
SDS-PAGE was performed using standard procedures [38].
Protein concentrations were routinely estimated using the Bio-
Rad Protein System, with bovine serum albumin as the standard.
Protease concentrations were determined by using the appropriate
extinction coefﬁcient (E1%/280 = 17.65 thermolysin, E1%/280 =
14.7 pepsin).
Graph plotting and curve ﬁttingwere carried out with KaleidaGraph
(Synergy Software, PA).
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